1-环丙基-7-[[2-[[叔丁氧羰基]氨基]乙基]氨基]-6-氟-1,4-二氢-4-氧代-3-喹啉羧酸 | 105589-00-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 1-环丙基-7-[[2-[[叔丁氧羰基]氨基]乙基]氨基]-6-氟-1,4-二氢-4-氧代-3-喹啉羧酸
• 英文名称: 7-((2-((tert-butoxycarbonyl)amino)ethyl)amino)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
• 英文别名: N-(tert-Butoxycarbonyl) Desethylene Ciprofloxacin；1-cyclopropyl-6-fluoro-7-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethylamino]-4-oxoquinoline-3-carboxylic acid
• CAS: 105589-00-2
• 化学式: C₂₀H₂₄FN₃O₅
• 分子量: 405.426
• InChiKey: LKODMWGXEQVSOF-UHFFFAOYSA-N

物化性质

• 熔点：
  230-232?C
• 沸点：
  620.9±55.0 °C(Predicted)
• 密度：
  1.401±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  108
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  1-环丙基-7-[[2-[[叔丁氧羰基]氨基]乙基]氨基]-6-氟-1,4-二氢-4-氧代-3-喹啉羧酸 生成 7-(2-氨基乙基氨基)-1-环丙基-6-氟-4-氧代喹啉-3-羧酸
  参考文献：
  名称：

  Gau; Kurz; Petersen, Arzneimittel-Forschung/Drug Research, 1986, vol. 36, # 10, p. 1545 - 1549

  摘要：

  DOI：
• 作为产物：
  描述：

  N-叔丁氧羰基-1,2-乙二胺 、 1-环丙基-6,7-二氟-1,4-二氢-4-氧喹啉-3-羧酸 以 吡啶 为溶剂， 生成 1-环丙基-7-[[2-[[叔丁氧羰基]氨基]乙基]氨基]-6-氟-1,4-二氢-4-氧代-3-喹啉羧酸
  参考文献：
  名称：

  Gau; Kurz; Petersen, Arzneimittel-Forschung/Drug Research, 1986, vol. 36, # 10, p. 1545 - 1549

  摘要：

  DOI：

文献信息

• Developing ciprofloxacin analogues against plant DNA gyrase: a novel herbicide mode of action
  作者：Michael D. Wallace、Nidda F. Waraich、Aleksandra W. Debowski、Maxime G. Corral、Anthony Maxwell、Joshua S. Mylne、Keith A. Stubbs

  DOI：10.1039/c7cc09518j

  日期：——

  The development of ciprofloxacin analogues against plant DNA gyrase, a novel herbicidal target, with increased herbicidal activity and diminished antibacterial activity is described.

  描述了对植物DNA旋转酶的环丙沙星类似物的开发，这是一种新的除草靶标，具有增强的除草活性和减弱的抗菌活性。
• Macrolides
  申请人：Alihodzic Suleman

  公开号：US20050080025A1

  公开（公告）日：2005-04-14

  The present invention relates to 14 or 15 membered macrolides substituted at the 4 th position of formula (I) and pharmaceutically acceptable salts and solvates thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical bacterial infections in a human or animal body.

  本发明涉及在式(I)的第4位取代的14或15成员大环内酯及其药学上可接受的盐和溶剂化物，以及它们的制备方法和在人或动物体内治疗或预防系统性或局部细菌感染的用途。
• Identification of a potent small-molecule inhibitor of bacterial DNA repair that potentiates quinolone antibiotic activity in methicillin-resistant Staphylococcus aureus
  作者：Carine S.Q. Lim、Kam Pou Ha、Rebecca S. Clarke、Leigh-Anne Gavin、Declan T. Cook、Jennie A. Hutton、Charlotte L. Sutherell、Andrew M. Edwards、Lindsay E. Evans、Edward W. Tate、Thomas Lanyon-Hogg

  DOI：10.1016/j.bmc.2019.06.025

  日期：2019.10

  The global emergence of antibiotic resistance is one of the most serious challenges facing modern medicine. There is an urgent need for validation of new drug targets and the development of small molecules with novel mechanisms of action. We therefore sought to inhibit bacterial DNA repair mediated by the AddAB/RecBCD protein complexes as a means to sensitize bacteria to DNA damage caused by the host immune system or quinolone antibiotics. A rational, hypothesis-driven compound optimization identified IMP-1700 as a cell-active, nanomolar potency compound. IMP-1700 sensitized multidrug-resistant Staphylococcus aureus to the fluoroquinolone antibiotic ciprofloxacin, where resistance results from a point mutation in the fluoroquinolone target, DNA gyrase. Cellular reporter assays indicated IMP-1700 inhibited the bacterial SOS-response to DNA damage, and compoundfunctionalized Sepharose successfully pulled-down the AddAB repair complex. This work provides validation of bacterial DNA repair as a novel therapeutic target and delivers IMP-1700 as a tool molecule and starting point for therapeutic development to address the pressing challenge of antibiotic resistance.
• 14 OR 15 MEMBERED MACROLIDES WITH ANTIBACTERIAL ACTIVITY
  申请人：GLAXO GROUP LIMITED

  公开号：EP1453846B1

  公开（公告）日：2007-05-16
• US7202221B2
  申请人：——

  公开号：US7202221B2

  公开（公告）日：2007-04-10